Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
161results about How to "Expand the scope of clinical application" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bionic alginate composite antimicrobial dressing and preparation method thereof
ActiveCN103908693AImprove mechanical propertiesPromote absorptionAbsorbent padsBandagesProcess systemsCross-link
The invention belongs to the field of biomedical materials, and particularly relates to bionic alginate composite antimicrobial dressing and a preparation method thereof. The bionic alginate composite antimicrobial dressing is prepared from the following raw materials: alginate components, chitosan components and silver ion components. The method is characterized by comprising the following steps: adding deionized water to agitate a solvent after mixing the raw materials, so as to obtain mixed water gel; repeatedly thawing, freezing and drying the mixed water gel to obtain a product, wherein the product comprises the following raw materials by weight percent: 60-90% of alginate components, 9.8-39% of chitosan components and 0.2-1% of silver ion components. The process system disclosed by the invention is controllable in temperature and condition, the problems of residues such as a toxic cross-linking agent or an assistant and the like do not exist, the safety risk of clinical application is greatly reduced, and the bionic alginate composite antimicrobial dressing has good product transformation feasibility.
Owner:山东颐诺生物科技有限公司
Lanthanide rare earth coordinated cellulose medical material and preparation method thereof
ActiveCN104277124AGood antibacterial effectPromote degradationAbsorbent padsBandagesCelluloseWound dressing
The invention discloses a lanthanide rare earth coordinated cellulose medical material and a preparation method thereof. The medical material is prepared by oxidizing primary hydroxyl of cellulose into carboxyl and then coordinating with lanthanide rare earth metal ions, namely performing sol-gel self-assembling reaction to rare earth metal hydrate and cellulose the primary hydroxyl of which is selectively oxidized into carboxyl. The preparation method is simple in preparation technology and good in controllability. The material not only has excellent moisture absorption and preservation properties and breathability, and better biocompatibility and excellent degradability of cellulose materials, but also has antibacterial property of the rare earth complex, can be used for antibacterial and bacteriostasis wound dressing due to broad-spectrum antibacterial property, and can also be used for detection tracing, special marking and optical display of biomolecules; the lanthanide rare earth coordinated cellulose medical material can be prepared into powder, gel, thin films, sponge or other porous materials, thus expanding the clinical application range; and the lanthanide rare earth coordinated cellulose medical material can be doped or grafted with macromolecular compounds so as to enhance the antibacterial and bacteriostasis properties and promote therapeutic effect on wound recovery.
Owner:山东省医疗器械研究所
Preparation method and application of quick absorption saturation gelation seaweed hemostatic dressing
InactiveCN104338173ARaw materials are easy to getLow priceFibre treatmentDry-cleaning apparatus for textilesSurgical operationFiber
The invention discloses a preparation method of a quick absorption saturation gelation seaweed hemostatic dressing. The method includes the steps of: soaking, rinsing and drying on calcium fiber textile or non-woven products containing alginate, and the carrying out cutting, packaging and sterilizing to obtain the quick absorption saturation gelation hemostatic dressing. The invention also discloses the application of the quick absorption saturation gelation seaweed hemostatic dressing prepared by the above method. The invention is applicable to rapid absorption and removal of a large amount of surgical diffusate in surgical operation process, so as to realize the effects of rapid hemostasis and operation wound clean; the hemostatic dressing is used for burn, scald and other acute and chronic wounds, can cover the wound and prevent moisture loss in body fluids, provide a positive moist environment for wound healing, prevent the wound from effusion and erosion, isolate bacterial infection, and play the effects of stopping bleeding, relieving pain, promoting wound healing, and reducing scar.
Owner:许春晖 +1
Alginic acid-chitosan composite fiber for tranma repairing and preparation method thereof
InactiveCN103469365APromote healingImprove mechanical propertiesAbsorbent padsConjugated artificial filamentsFiberChemical reaction
The invention belongs to the field of biomedical materials, and particularly discloses an alginic acid-chitosan composite fiber for tranma repairing and a preparation method thereof. The alginic acid-chitosan composite fiber for the tranma repairing is characterized by comprising an alginic acid component of which the mass fraction is 50-95%, and a chitosan component of which the mass fraction is 5-50%. The processing technique disclosed by the invention is not involved with an organic reagent or an organic chemical reaction, so that the preparation method is mild in reaction system and controllable in condition; the residue problems of a toxic crosslinking agent or an assistant and the like do not exist; used materials, reagents and the like have good biosecurity; the security risk of clinical applications is greatly reduced. In addition, the technology disclosed by the invention is simple and controllable, and has the good product transformation feasibility; the difficulty of risk management in the preparation process is greatly reduced.
Owner:山东颐诺生物科技有限公司
Bone marrow stem cell protection solution and preparation method thereof
InactiveCN107668024AEffective protectionExpand the scope of clinical applicationDead animal preservationCell activityInosamycins
The present invention provides a bone marrow stem cell protection solution, which is mainly prepared by dissolving a hypoxic protection agent, heparin sodium and an aminoglycoside antibiotic in a DMEM / F12 culture medium aqueous solution, wherein per mL of the DMEM / F12 culture medium aqueous solution can respectively dissolve 5-10 mg of the hypoxic protection agent, 0.01-0.05 U of the heparin sodium and 50-200 U of the aminoglycoside antibiotic, and the concentration of the DMEM / F12 culture medium aqueous solution is 30-40 mg / ml. According to the present invention, the bone marrow stem cell protection solution has advantages of stable performance, safety and no toxicity, can effectively protect bone marrow stem cells, can make bone marrow stem cells be preserved for a long time and can maintain the cell activity in vitro, can maintain the original multidirectional differentiation ability, and can expand the clinical application of bone marrow stem cells, wherein the bone marrow stem cells can be transported to most domestic cities and neighboring countries by using the existing transportation tools.
Owner:CENTURY BIOSTRENGTH BEIJING PTY LTD
Enrofloxacin slow-release micropill for livestocks, and preparation method of same
InactiveCN102648896AExpand the scope of clinical applicationImprove the characteristics of easy color change when exposed to lightAntibacterial agentsOrganic active ingredientsPharmaceutical formulationSodium carboxymethyl starch
The invention relates to the field of pharmaceutical preparations and particularly relates to a slow-release micropill preparation containing enrofloxacin and a preparation method of the preparation. The slow-release micropill provided by the invention is formed by coating an enrofloxacin micropill; the enrofloxacin micropill comprises enrofloxacin and auxiliary material and is formed through extruding and rounding; the auxiliary material is any one or more of microcrystalline cellulose, starch, cane sugar, artificial gum, lactose and sodium carboxymethyl starch; according to weight percent, the auxiliary material in the micropill accounts for 70% to 95%; and coating is made of high-molecular enteric material, film forming material, opaquer and the like. The slow-release micropill preparation has the characteristics of slow release and high bioavailability, can be used for treating bacteria and mycoplasma infection of livestocks, and has better curative effect on chronic respiratory diseases, colibacillosis and salmonellosis, and the frequency of medicine taking can be reduced; and in addition, the slow-release micropill provided by the invention has the advantages that the stability of medicine is improved, and peculiar bitter of enrofloxacin can be covered completely, so that feeding intake of the animals is not influenced, and the recovery rate is improved.
Owner:ZHENGZHOU FUYUAN ANIMAL PHARMA
Enramycin dry suspension and preparation method thereof
InactiveCN102949348AEvenly distributedImprove stabilityAntibacterial agentsPowder deliveryBiotechnologyEnramycin
The invention provides enramycin dry suspension which contains 2 percent to 8 percent of enramycin, 20 percent to 60 percent of filler, 10 percent to 40 percent of flavoring, 5 percent to 30 percent of suspending aid and 1 percent to 10 percent of wetting agent. In addition, the invention provides a preparation method of the enramycin dry suspension. Compared with premix, when being used temporarily, the enramycin dry suspension can be dispersed into supensoid agent for oral taking only by being added with water and shaken; when being used, the enramycin dry suspension can become solution only by being added with water, the dispersion is uniform, and the defects when the premix is used are overcome; meanwhile, the specific surface area of the enramycin dry suspension is larger than that of the premix, the absorption is quick, the bioavailability is high and the cure rate is higher. Compared with the solution, the enramycin dry suspension is always in a dry state without water, so that the stability is more easily realized. In addition, the enramycin dry suspension is conveniently used, so that a lot of manpower and materials are saved. But a technology of preparing dry suspension with the enramycin is not yet reported.
Owner:GUANGDONG RONGDA BIOENG CO LTD +2
Etimicin sulfate preparation and its preparing method
InactiveCN1569010AAdd new varietiesExpand the scope of clinical applicationOrganic active ingredientsAntipyreticChemistrySulfuric acid
The invention discloses etimicin sulfate preparation and its preparing method which comprises, charging acids or alkali as pH conditioning agent so as to increase the dissolving degree of the etimicin, charging right amount of isoosmotic adjustment agent, thus resulting the action of quick sterilization.
Owner:ZHEJIANG UNIV
Application of paeonol for preventing and treating fatty liver disease
InactiveCN1919187AEstablish the basis for treatmentLow priceDigestive systemPharmaceutical delivery mechanismFatty liverFluid infusion
Disclosed is the use of paeonol in preparing medicament for the prevention or treatment of fatty liver, and also the use of medicinal combination preparation of paeonol with medicinal carrying agent in preparing medicaments for the prevention and treatment of fatty liver disease, the dose forms of the medicament include soft capsules, drop pills, pills, powders, tablets, capsules, granules, injections, fluid infusions, freeze-dried powders for injection, suppositories, film agents, tiny capsules, tincture, syrup, oral liquids and other pharmaceutically acceptable dose forms.
Owner:戴敏
Classical prescription medicine intelligent dialectical treatment system based on big data
InactiveCN107945869AEffectively promote and promoteExpand the scope of clinical applicationHealth-index calculationMedical automated diagnosisDiseaseMedicine
The invention discloses the technical field of medical devices, and particularly relates to a classical prescription medicine intelligent dialectical treatment system based on big data. The system isbased on a modern mobile information platform to complete the collection of information of 'seeing, smelling, asking and pulse-taking. The overall guidance of the system is 'eight-class syndrome differentiation'. The dialectical method of 'six-meridian syndrome differentiation' in 'Treatise on Febrile Diseases' is used. The traditional Chinese medicine theory is combined, and when dialectic is carried out, disease differentiation is carried out on a patient. Mutual reference of diseases and intelligent diagnosis of traditional Chinese medicine are realized. Finally, guidance classic prescription medicine is provided. The modern research results and clinical experience of classic prescription medicine are fully absorbed. The clinical application scope of classic prescription medicine is effectively expanded. Due to the fact that the system has less hardware and is simple and portable, the system can be widely accepted by the general public, and can effectively popularize and promote traditional Chinese medicine.
Owner:李玉东
Method for quickly and accurately calibrating medical imaging component after changing of position thereof
Owner:WEIDU MEDICAL SYST
Thrombectomy system and controllable thrombectomy apparatus thereof
ActiveCN104840235AControllable shapeExpand the scope of clinical applicationSurgeryThrombusEngineering
The invention discloses a thrombectomy system and a controllable thrombectomy apparatus thereof. Emboli can be taken out by a mechanical embolus taking device, accordingly, blood vessels can be dredged, and blood vessel recanalization effects can be realized. The controllable thrombectomy apparatus is provided with a thrombectomy spring. The thrombectomy spring in a release state is in the shape of a cone screw, a core thread is connected to a distal end of the thrombectomy spring, a tubular structure is connected to a proximal end of the thrombectomy spring, the core thread is slidably connected with the tubular structure, and the shape of the thrombectomy spring can be controlled. Compared with the prior art, the thrombectomy system and the controllable thrombectomy apparatus have the advantages that the shape of the thrombectomy spring can be controlled, only a space with the length not larger than 10mm needs to be provided at a distal end of a required embolism position when the apparatus is about to be released, accordingly, the clinical applicable range can be extended to a great degree, the apparatus is quite flexible, the minimum passing size of the apparatus is 0.014' (0.36mm), and the apparatus can easily enter the small tortuous blood vessels.
Owner:湖南瑞康通科技发展有限公司
Ultrasonic probe inside vagina with changeable detection direction and device
ActiveCN101411628AEffective Scanning and SurveillanceExpand the scope of clinical applicationSurgeryCatheterUltrasonic sensorLeft direction
The invention relates to a gynaecologic ultrasonic probe capable of changing the direction of a probe body, which comprises the probe body which consists of an ultrasonic sensor and a shell of the ultrasonic sensor, a cable conductor which is connected with the ultrasonic sensor, and a cable conductor shell, wherein a free swinging section is arranged between the probe body shell and the cable conductor shell; and a regulation and control box which is used for controlling rotation of the probe body is arranged on the other end of the cable conductor shell. The ultrasonic probe on the regulation and control box part can efficiently deflect the probe body placed on anterior fornix or posterior fornix in the left direction, the right direction, the up direction, the down direction or the combined direction, not only can efficiently scan and monitor an uterus body on various positions and is suitable to be used for various gynaecologic operations but also can monitor different positions when the same operation is performed and improve the operation efficiency and accuracy, and has good application effect, novel and reasonable structural design, good localizability and convenient use, and is particularly favorable for promotion and implementation.
Owner:河南方正医用电子有限公司
Preparation method of low-anticoagulant heparin with anti-tumor activity
InactiveCN102924627AReduced anticoagulant activityReduce the number of anticoagulant active sitesAntineoplastic agentsEnzymatic synthesisSide effect
The invention belongs to the field of biomedicine technique, and particularly relates to a preparation method of low-anticoagulant heparin with anti-tumor activity. The method comprises the steps of using heparin as a starting material to prepare completely desulfated heparin, carrying out N- site resulfation, carrying out enzymatic synthesis to obtain specific-site sulfated heparin through combination of Arylsulfotransferase-IV (AST-IV), 6-OST-1 and 2-OST by a 3'-phosphoadenosine-5'-phosphosulfate (PAPS) regeneration system based on the substances obtained in the previous steps, and carrying out N- site sulfation on the specific-site sulfated heparin to obtain the final low-anticoagulant activity heparin derivative with specific anti-tumor function.The heparin derivative avoids the side effects such as bleeding, decrease of blood platelet and osteoporosis when common heparin is used for the tumor patients, and is beneficial to expanding the clinical application ranges of the heparin drugs.
Owner:JIANGNAN UNIV
Lyophilized reagent capable of simultaneously distinguishing three pathogen nucleic acids
InactiveCN108411037AImprove stabilityAmplified detectionMicrobiological testing/measurementMicroorganism based processesLiquid nitrogenReaction system
The invention discloses a lyophilized reagent for nucleic acid diagnosis. The lyophilized reagent comprises a lyophilized protecting agent which contains 2%-10% of trehalose, 2%-5% of glucan, 0.5%-2%of PEG8000 and 0.01mg-0.02mg / ml of BSA protein, and the lyophilized protecting agent contains mycoplasma pneumoniae, chlamydia pneumoniae and adenovirus primers and probes. The lyophilized reagent hasadvantages that since the lyophilized reagent contains three pathogen nucleic acids of mycoplasma pneumoniae, chlamydia pneumoniae and adenovirus, amplification detection of various pathogen nucleicacids can be realized, namely three targets can be simultaneously detected by one reaction system, and accordingly reagent and detection consumables are greatly saved, high detection throughput is realized, and a clinical application range is expanded. In application of the lyophilized reagent for lyophilization treatment, liquid nitrogen is adopted for quick pre-freezing of a liquid reagent, so that a subsequent lyophilization process is shortened, and stability of the lyophilized reagent is improved.
Owner:AUTOBIO DIAGNOSTICS CO LTD
Dispersion tablet for treating cardiovascular diseases and its preparation method
InactiveCN1827112ADisintegrates quicklyFast absorptionOrganic active ingredientsPill deliveryCelluloseCoronary artery disease
This invention discloses a disperse tablet for cardiovascular disease therapy and its preparing method. Firstly dry raw materials separately and pass them through 100 orders screen; then adopting equivalent incensement method, mix D with micro-crystal cellulose, gelatinized starch, hydropropyl cellulose, acepaten and crosslinked polyketone, execute it to soft material by 2% hydropropyl methylcellulose, pass the soft material through20 orders screen to produce grains, dry the grains in bake oven at 60deg C, treat the grains, add micronized powder silica gel and stearate, mix, tablet and package is ok. This invention has the characteristics of disintegration rapid, absorption quick, biology availability high, adverse affects few and taking convenient. It has efficacies of promoting Qi and blood, and activate collaterals to relieve pain, it can be used to cure thorax paralysis, heartache and intermittent pulse caused by qi stagnation and blood silt, and coronary disease, arrhythmia with above symptoms. It is especially available to old people and patients difficult to swallow solid.
Owner:曹明成
Compressive sensing computer tomography image reconstruction method based on p-norm
ActiveCN104867168AReduce scan timeReduce Motion Artifacts2D-image generationHat matrixReconstruction method
The invention discloses a compressive sensing computer tomography image reconstruction method based on a p-norm, and particularly to a CT image algebraic reconstruction method which performs image total variation Lp norm minimizing on incomplete projection data. The method mainly comprises the steps of (1) acquiring a CT system imaging parameter and scanning system projection data; (2) initializing the projection data, performing discrete processing and filtering noise-reduction processing on the projection data by means of a wavelet transformation base, solving a projection matrix through weighting and performing assignment x(0)=0 on an initial image x; and (3) performing algebraic reconstruction on the projection data, performing total variation Lp norm minimizing adjustment on the image after iteration each time by means of a gradient decent algorithm, and determining whether a convergence condition is satisfied. If the convergence condition is satisfied, the reconstructed image is stored and output; and otherwise, continuing iteration in a manner that the adjusted image which is iterated this time as an interaction initial value.
Owner:NANJING UNIV OF POSTS & TELECOMM
High-strength and high-corrosion-resistance biomedical Mg-Ga alloy and preparation method thereof
The invention aims to provide a high-strength and high-corrosion-resistance biomedical Mg-Ga alloy and a preparation method thereof. The alloy comprises the following chemical components of, by weight, 4.5%-10.0% of Ga and the balance Mg element and other inevitable impurities. By adding a proper amount of the Ga element is added into a pure magnesium matrix, alloy grains can be refined, and the mechanical strength and the corrosion resistance of the alloy are improved. In addition, a Zn element can be added, the Mg-Zn-Ga phase can be separated from the alloy by adjusting a heat treatment system, so that the alloy is further strengthened. The alloy is excellent in biocompatibility, has the biological functions of promoting bones and the like, and is a multifunctional biomedical degradablemagnesium alloy material with excellent comprehensive performance, and has an important application value in the medical fields such as orthopedic implants.
Owner:烟台浩忆生物科技有限公司
Coccidiostat-decoquinate dry suspension for livestock and poultry and preparation method thereof
ActiveCN101559074ASolve the use restriction of not being able to drink water to administer medicinesExpand the scope of clinical applicationPowder deliveryPharmaceutical non-active ingredientsCoccidiostatsCoccidiostat
The invention relates to a coccidiostat-decoquinate dry suspension for livestock and poultry and a preparation method thereof. The coccidiostat comprises the following main components in portion by weight: 2 to 6 portions of decoquinate, 5 to 20 portions of non-ionic surfactant, and 30 to 90 portions of glauber salt. The preparation method comprises the following steps that: the decoquinate is added into the non-ionic surfactant, and the mixture is stirred evenly; and then the glauber salt is added into the mixture, and a finished product is prepared by stirring evenly, drying, crushing and sieving. The dry suspension is prepared from the decoquinate by adding the non-ionic surfactant and the glauber salt, solves the service restriction problem that the decoquinate fails to be taken by drinking water, greatly improves the clinical application range of decoquinate medicaments, and has broad application prospect.
Owner:TIANJIN ZHONGSHENG TIAOZHAN BIOTECH
Application of dihydromyricetin in preparation of medicines for inhibiting adriamycin cardiotoxicity
InactiveCN103315993ACardiotoxicity Prevention and MitigationImprove protectionOrganic active ingredientsAntineoplastic agentsApoptosisIn vivo
The invention provides an application of a dihydromyricetin composition in preparation of medicines for inhibiting adriamycin cardiotoxicity. The composition is composed of dihydromyricetin and adriamycin; as shown by in vivo and in vitro experimental studies, the dihydromyricetin can inhibit cell apoptosis activated by the adriamycin and dependent to mitochondrial membrane potential so as to reduce lethality caused by adriamycin cardiotoxicity, and the composition provided by the invention has excellent protection effect on cardiotoxicity induced by adriamycin. The composition provided by the invention can be used for preventing and alleviating the cardiotoxicity educed by adriamycin and has clinical practicability.
Owner:ZHEJIANG UNIV
Application of conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia
ActiveCN107789628AReduce clinical adverse reactionsReduce the number of dosesAntipyreticAnalgesicsPolyethylene glycolDosing Frequency
The invention discloses application of a conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia. The local anesthetic is made into a prodrug or a sustained release preparation, wherein high-molecular polymers such as polyethylene glycol in the prodrug are covalently bonded with local anesthetic, and auxiliary materials with a sustained release function in the sustained release preparation are covalently bonded with the local anesthetic. After application of the conjugate, anesthesia and analgesia effects are not achieved until release of free local anesthetic, and an analgesia effect is achieved after release of the free local anesthetic. Due to low release speed of the prodrug or the sustained release preparation of the local anesthetic, drug concentration can bestably and enduringly kept in an effective concentration range of non-narcotic analgesia, long-acting non-narcotic analgesia effects can be achieved while remarkable reduction of clinical untoward effects of the local anesthetic and reduction of dosing frequency are realized, drug effectiveness is improved, and a clinical application range of the local anesthetic is expanded.
Owner:JENKEM TECH CO LTD (LIAONING)
Sustained releasing formulation of compound glucosamine, preparation process and application thereof
InactiveCN1961887ASafe releaseSmooth releaseOrganic active ingredientsAntipyreticSide effectVolumetric Mass Density
The invention relates to a composite slow-release agent, wherein it contains indomethacin, aminoglucose salt, slow-release material and other findings, while their ratios are 5-45%, 20-80%, 1-75%, and the left is findings. Its preparation comprises that mixing indomethacin and / or aminoglucose salt, and slow-release material and / or packs, then adding other findings, using general slow-release technique to obtain one or several skeleton or mould-contoro slow-release agent. The invention can be made into particle, oral, tablet or capsule. The invention can keep stable blood drug density in 8-36h, reduce side effect.
Owner:ZHEJIANG HAILISHENG PHARM CO LTD
Switching device for composite radio frequency and irreversible electroporation
PendingCN113397689AImprove the effectiveness of treatmentExpand the scope of clinical applicationSurgical instruments for heatingPower conversion systemsRadiofrequency ablationCurrent sensor
The invention discloses a switching device for composite radio frequency and irreversible electroporation. The switching device for the composite radio frequency and the irreversible electroporation comprises an alternating current and direct current switching module and a current sensor switching module and is used for outputting high-voltage direct current pulses for irreversible electroporation and radio frequency sine waves output by radio frequency ablation to two external electrode interfaces in a time-sharing switching mode, the switching device is respectively connected with the output of a DCAC inverter circuit of the radiofrequency ablation module, a high-voltage direct current output of a irreversible electroporation module, a control interface of a main control board and a electrode interface. Compared with the prior art, ablation working modes can be switched according to needs, irreversible electroporation ablation treatment is carried out, and needle passage ablation can be carried out through low-power ablation mode output when irreversible electroporation ablation treatment is finished. The switching device can be used for common focuses as a radiofrequency ablation host. The treatment effectiveness of the irreversible electroporation equipment is improved, a compound treatment mode of irreversible electroporation and radiofrequency ablation can be carried out on some complex cases, and the clinical application range of the device is greatly widened.
Owner:ZHEJIANG JIANAIWEI MEDICAL TECH
Water solution of penciclovir and its prepn. method
InactiveCN1461643AImprove solubilityExpand the scope of clinical applicationAntiviralsHeterocyclic compound active ingredientsDiseaseHerpes zoster virus
A water soluble of Penxiluowei contains the Penxiluowei or its salt, solubilizer, cosolvent and pH regulator. It can be used to prepare injection, eye drops and nose drops for treating the diseases caused by herpes simple virus, herpes zoster virus and hepatitis B virus.
Owner:XICHUAN INST OF ANTIBIOTIC IND NAT MEDICINE SUPERVISION BUREAU
Nano hybrid silk fibroin hydrogel and preparation method and application thereof
ActiveCN110917400ARapid gelationAvoid the use of chemical crosslinkersPharmaceutical delivery mechanismTissue regenerationFibroinStem like cell
The invention discloses a nano hybrid silk fibroin hydrogel and a preparation method and application thereof, and belongs to the technical field of biomedical materials. The nano hybrid silk fibroin hydrogel is prepared by pre-blending a regenerated silk fibroin aqueous solution and nano hydroxyapatite and performing ultrasonic treatment. According to the preparation method of the nano hybrid silkfibroin hydrogel, the ultrasonic condition and the mixing ratio of the two materials are changed, the gelation time is controlled, and rapid gelation is realized, so that use of a potentially toxic chemical crosslinking agent is avoided, and activity of cells or biological factors can be well maintained. The nano hybrid silk fibroin hydrogel provided by the invention has controllable gel performance, controllable mechanical performance, good cell compatibility and good bone induction capability, can load stem cells for repairing bone defect, and is expected to be used for embedding active factors for synergistic treatment.
Owner:SUN YAT SEN UNIV
Method for preparing absorbent fibrin hemostatic plaster
InactiveCN1602967AWith biochemical hemostasisFunctionalAbsorbent padsBandagesFreeze-dryingBiocompatibility Testing
The invention which belongs to medical instrument techmology field involving a preparation method of hemostasis tiedan that can absorb fibrous protein.This method is that adding the roboflavin,fibrinogen and thrombin freeze dry powder according to certain proportion into the mortar,then add anhydrous ethanol to the mortar and stirring into uniform distribution suspension,then put the uniform distribution into the flat chassis to make the surface of adhesive olynthus contact,at last,the adhesive olynhus which adhesion of mixed dry powder particle is vacuumized and drying disinfected.The hemostasis tiedan that mentioned in this invention is good at the body biocompatibility and can be degradated in vivo thoroughly.This hemostasis tiedan which is combined with the biochemical hemostasis and mechanical hemostasis can not only rein up capillary permeability blood,also can rein up the arterioles and vein hemorrhage,so that expanding the range of the clinical application greatly and this hemostasis tiedan can be used to hemostasis of visceral operation and large body surface trauma.Also,this hemostasis tiedan increase the function of drug release and partial administration by adding antibiotics and anticancer drug in the glue olynthus.
Owner:深圳奇源康生物医学有限公司
Amnion contact lens, preparation method and application
PendingCN110123520AImprove securityPromote orderly growthSenses disorderAntipyreticControlled releaseOrganic solvent
The invention relates to the field of medicine, discloses an amnion contact lens, a preparation method and application and aims to solve problems that existing contact lenses are insufficient in drugloading capacity and organic solvents are prone to injuring the amnion and the cornea and causing cornea tissue scarring. The amnion contact lens comprises a contact lens body, the amnion, first water-water microdroplets and second water-water microdroplets. The first water-water microdroplets are arranged on the inner surface of an optical area of the contact lens body; the amnion is adhered on the inner surface of an optical area of the contact lens body through the first water-water microdroplets; the second water-water microdroplets are adhered to the inner surface of the amnion. Controlled-release medicines are wrapped in the second water-water microdroplets, and the contact lens has advantages of foldability, hydrophobicity and breathability.
Owner:GUANGDONG PROPHET BIOTECHNOLOGY CO LTD
Growth hormone controlled-release coating and preparation method thereof
InactiveCN108465104AReduce contact dissolution rateMaintain integrityPeptide/protein ingredientsMetabolism disorderReaction ruleSuperhydrophobic coating
The invention belongs to the technical field of biomedical technologies, and discloses a growth hormone controlled-release coating and a preparation method thereof. The coating comprises three layersof structures which are an outermost layer superhydrophobic coating, a middle layer silk fibroin peptide coating and an innermost layer growth hormone controlled-release microballoon sphere. The invention aims at providing a preparation method of an oral administration dosage form. The three layers of structures with different ingredients are targetedly arranged to serve as the coating of growth hormone according to the structure and reaction rules of human digestive tracts, an advanced electrostatic spraying technology is adopted for making the coating, the number of times of administration of a patient is reduced, the growth hormone medicine clinical application range is increased, and the coating has the wide market prospect.
Owner:FOSHAN SHIRUI LEADING MATERIAL RES INST GENERAL PARTNERSHIP
Coccidiostat-decoquinate dry suspension for livestock and poultry and preparation method thereof
ActiveCN101559074BSolve the use restriction of not being able to drink water to administer medicinesExpand the scope of clinical applicationPowder deliveryPharmaceutical non-active ingredientsCoccidiostatsCoccidiostat
Owner:TIANJIN ZHONGSHENG TIAOZHAN BIOTECH
Cannabidiol self-nanoemulsion buccal membrane preparation as well as preparation method and application thereof
ActiveCN113209052AImprove bindingDoes not affect mechanical propertiesNervous disorderHydroxy compound active ingredientsActive agentBioadhesive
The invention discloses a cannabidiol self-nanoemulsion buccal membrane preparation as well as a preparation method and application thereof. The bioadhesive membrane comprises a backing membrane and a bioadhesive membrane layer adhered to the backing membrane, wherein the bioadhesive film layer is formed by dispersing cannabidiol in a self-nanoemulsion system, adsorbing the cannabidiol by a solid carrier and then dispersing the cannabidiol in a film-forming polymer, and the self-nanoemulsion system comprises an oil phase, a surfactant and a cosurfactant. According to the cannabidiol self-nanoemulsion buccal membrane preparation disclosed by the invention, the cannabidiol is in a supersaturated dissolved state in an oil phase, the solubility of the cannabidiol in a system is improved, nano-scale liquid drops formed by the self-nanoemulsion promote permeation and absorption of the cannabidiol in buccal mucosa, the taking effect time of a medicine is shortened, and the bioavailability of the medicine is improved. The cannabidiol self-nanoemulsion buccal membrane preparation disclosed by the invention can be applied to the aspects of resisting epilepsy, easing pain, treating mental diseases (such as schizophrenia, division affective disorder and delusional disorder), resisting anxiety, resisting depression and the like.
Owner:NEOFORM BIOPHARMACEUTICAL LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com